Scagliotti GV, et al. Nintedanib + pemetrexed/cisplatin in patients with unresectable MPM: phase III results from the LUME-Meso trial. IASLC 2018, abstract PL02.09.
AI-biomarker voor respons op atezolizumab-bevacizumab bij HCC
jan 2024 | Maag-darm-leveroncologie